Connect with us

Health

Novo Nordisk’s Wegovy pill recommended for EU Approval

SHARE:

Published

1 month ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for the Wegovy pill. Already approved in the US, the pill has seen huge uptake, with more than 1 million people using it within the first 4 months of its launch.

Developed by Novo Nordisk, it is intended for adults living with obesity, or those who are overweight and have at least one weight-related comorbidity, such as cardiovascular disease, hypertension, or type 2 diabetes.

The new oral formulation could broaden access for patients reluctant to use injections. Unlike some competing oral therapies, Wegovy pill also carries no drug-drug restrictions in its proposed label where one medicine can react with another producing harmful side effects.

“We are encouraged by CHMP’s positive opinion for Wegovy pill,” said Novo...

Share this article:

Share this:
Related Topics:
Guest Contributor - Opinion

Opinions expressed are purely those of the author and not endorsed by EU Reporter. The article was unsolicited by EU Reporter, and the author guarantees the truthfulness of the contents of the article. No payment was made by EU Reporter to the author

EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending